Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation
CONCLUSION: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.PMID:38035562 | DOI:10.1159/000535583 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Tai Yeon Koo Juhan Lee Yonggu Lee Hyung Woo Kim Beom Seok Kim Kyu Ha Huh Jaeseok Yang Source Type: research
Anticoagulation in Patients with Chronic Kidney Disease
Am J Nephrol. 2023 Nov 30. doi: 10.1159/000535546. Online ahead of print.ABSTRACTBACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD.SUMMARY: In post-...
Source: American Journal of Nephrology - November 30, 2023 Category: Urology & Nephrology Authors: Elias John Elenjickal Christoforos K Travlos Pedro Marques Thomas A Mavrakanas Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study
Conclusion Rituximab was proven an effective and safe treatment option for adult FR/SDNS patients with MCD or FSGS in maintaining disease remission and minimizing corticosteroid exposure.PMID:37963441 | DOI:10.1159/000535010 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 14, 2023 Category: Urology & Nephrology Authors: Lan Lan Yuxin Lin Binfeng Yu Yin Wang Hong Pan Huijing Wang Xiaowei Lou Xiabing Lang Qiankun Zhang Lie Jin Yi Yang Liang Xiao Jianghua Chen Fei Han Source Type: research
